The growing prevalence for performance-enhancing peptides has spawned a significant grey market, offering both unique possibilities and real risks. These unlicensed products, often obtained from international manufacturers, bypass traditional pharmaceutical processes, allowing access at reduced prices. However, the absence of quality control and… Read More